Literature DB >> 2458359

Two independent mechanisms for escaping epidermal growth factor-mediated growth inhibition in epidermal growth factor receptor-hyperproducing human tumor cells.

M Hirai1, S Gamou, S Minoshima, N Shimizu.   

Abstract

Human squamous cell carcinoma cell lines often possess increased levels of epidermal growth factor (EGF) receptor. The growth of these EGF receptor-hyperproducing cells is usually inhibited by EGF. To investigate the mechanism of EGF-mediated inhibition of cell growth, variants displaying alternate responses to EGF were isolated from two squamous cell carcinoma lines, NA and Ca9-22; these cell lines possess high numbers of the EGF receptor and an amplified EGF receptor (EGFR) gene. The variants were isolated from NA cells after several cycles of EGF treatment and they have acquired EGF-dependent growth. Scatchard plot analysis revealed a decreased level of EGF receptor in these ER variants as compared with parental NA cells. Southern blot analysis and RNA dot blot analysis demonstrated that the ER variants had lost the amplified EGFR gene. One variant isolated from Ca9-22 cells, CER-1, grew without being affected by EGF. CER-1 cells had higher numbers of EGF receptor than parental Ca9-22 but similar EGFR gene copy number. Flow cytometric analysis indicated an increase in ploidy and cell volume which may give rise to the increase in receptor number per cell. The EGF receptors on both Ca9-22 and CER-1 cells were autophosphorylated upon EGF exposure in a similar manner suggesting no obvious alteration in receptor tyrosine kinase. However, very efficient down-regulation of the EGF receptor occurred in CER-1 cells. These data suggest two independent mechanisms by which EGF receptor-hyperproducing cells escape EGF-mediated growth inhibition: one mechanism is common and involves the loss of the amplified EGFR genes, and another is novel and involves the efficient down-regulation of the cell-surface receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458359      PMCID: PMC2115197          DOI: 10.1083/jcb.107.2.791

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  44 in total

1.  Different responses to EGF in two human carcinoma cell lines, A431 and UCVA-1, possessing high numbers of EGF receptors.

Authors:  S Gamou; Y S Kim; N Shimizu
Journal:  Mol Cell Endocrinol       Date:  1984-09       Impact factor: 4.102

2.  Analysis of the insulin receptor by anti-receptor antibodies and flow cytometry.

Authors:  R Maron; R A Jackson; S Jacobs; G Eisenbarth; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

3.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.

Authors:  A Ullrich; L Coussens; J S Hayflick; T J Dull; A Gray; A W Tam; J Lee; Y Yarden; T A Libermann; J Schlessinger
Journal:  Nature       Date:  1984 May 31-Jun 6       Impact factor: 49.962

4.  Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells.

Authors:  C R Lin; W S Chen; W Kruiger; L S Stolarsky; W Weber; R M Evans; I M Verma; G N Gill; M G Rosenfeld
Journal:  Science       Date:  1984-05-25       Impact factor: 47.728

5.  Epidermal growth factor inhibits the synthesis of the nuclear protein cyclin in A431 human carcinoma cells.

Authors:  R Bravo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

6.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

7.  EGF-ricin A conjugates: kinetic profiles of cytotoxic effects and resistant cell variants.

Authors:  N Shimizu; Y Shimizu; W K Miskimins
Journal:  Cell Struct Funct       Date:  1984-09       Impact factor: 2.212

8.  Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.

Authors:  T Kawamoto; J Mendelsohn; A Le; G H Sato; C S Lazar; G N Gill
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

9.  Comparison of protein phosphorylations in variant A431 cells with different growth responses to epidermal growth factor.

Authors:  J E Buss; C Chouvet; G N Gill
Journal:  J Cell Physiol       Date:  1984-06       Impact factor: 6.384

10.  Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells.

Authors:  G T Merlino; Y H Xu; S Ishii; A J Clark; K Semba; K Toyoshima; T Yamamoto; I Pastan
Journal:  Science       Date:  1984-04-27       Impact factor: 47.728

View more
  7 in total

1.  Purification of two distinct proteins of approximate Mr 80,000 from human epithelial cells and identification as proper substrates for protein kinase C.

Authors:  M Hirai; N Shimizu
Journal:  Biochem J       Date:  1990-09-15       Impact factor: 3.857

2.  Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth.

Authors:  Q Xiong; J L Chan; C S Zong; L H Wang
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Cell culture of human gingival fibroblasts, oral cancer cells and mesothelioma cells with serum-free media, STK1 and STK2.

Authors:  Yuta Tsugeno; Fuyuki Sato; Yasuteru Muragaki; Yukio Kato
Journal:  Biomed Rep       Date:  2014-06-27

4.  Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients.

Authors:  Phillip Kim; Xinjun Liu; Tani Lee; Limin Liu; Robert Barham; Richard Kirkland; Glen Leesman; Anne Kuller; Belen Ybarrondo; Shi-Chung Ng; Sharat Singh
Journal:  Proteome Sci       Date:  2011-12-15       Impact factor: 2.480

5.  Altered expression of epidermal growth factor receptor gene in a classical multidrug-resistant variant of a human cancer cell line, KB.

Authors:  H Takano; K Kohno; N Shiraishi; S Sato; K Asoh; M Yakushiniji; M Ono; M Kuwano
Journal:  Jpn J Cancer Res       Date:  1989-04

6.  Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study.

Authors:  Jacques Medioni; Mara Brizard; Reza Elaidi; Paul F Reid; Khadija Benlhassan; Dorothy Bray
Journal:  Contemp Clin Trials Commun       Date:  2017-07-23

7.  Lung cancer cells often express high levels of protein kinase C activity.

Authors:  M Hirai; S Gamou; M Kobayashi; N Shimizu
Journal:  Jpn J Cancer Res       Date:  1989-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.